Story

Moderna Receives FDA Approval for First mRNA-Based Influenza Vaccine

ENTHMSVIIDZHZH-TWJAKOHI
Aug 6, 20262 min read
Moderna Receives FDA Approval for First mRNA-Based Influenza Vaccine
Text size
Background

Moderna (NASDAQ: MRNA) announced Thursday it has secured U.S. Food and Drug Administration (FDA) approval for mFLUSIVA, its influenza vaccine for adults aged 50 and older. The decision marks the first U.S. approval for an mRNA-based flu shot and represents the fourth FDA-approved product for the biotechnology company.

Approval and Availability

According to Moderna, the company expects to begin supplying the vaccine to select U.S. retailers in the coming weeks, positioning it for the 2026-2027 respiratory virus season. The approval follows a unanimous recommendation from the FDA's Vaccines and Related Biological Products Advisory Committee.

This clearance expands Moderna's portfolio to five approved products globally. For investors, it signifies a critical step in diversifying the company's revenue streams beyond its well-known COVID-19 vaccine, demonstrating the broader applicability of its mRNA technology platform.

Clinical Trial Basis

The FDA's decision was based on data from a large-scale Phase 3 trial. Key details from the clinical program include:

Sample IUX Markets – In-articleAd
  • The study involved 40,805 adults aged 50 and older across 11 countries.
  • The company reported an acceptable safety profile with no new safety concerns identified during the trial.

For adults aged 65 and older, the vaccine received accelerated approval. This was based on immune response data from a separate U.S. trial involving 2,992 participants. Moderna will be required to conduct confirmatory post-marketing studies to verify the clinical benefit in this older demographic.

Market and Global Outlook

Chief Executive Stephane Bancel stated that the approval provides an important additional vaccination option for older adults, a population at higher risk for severe outcomes from influenza. The successful application of its mRNA platform to influenza is a strategic win for the company.

Moderna is also pursuing global approvals for mFLUSIVA. The company confirmed that regulatory applications are currently under review in the European Union, Canada, and Australia, with additional filings planned for later this year.

Read next

More on Stocks
Back to latest news

LATEST